Literature DB >> 19262721

Can the sequencing of concurrent capecitabine and radiation therapy improve the therapeutic ratio in rectal cancer?

Gary Y Yang1, Charles R Thomas.   

Abstract

Entities:  

Year:  2007        PMID： 19262721      PMCID： PMC2632868     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  10 in total

1.  Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).

Authors:  Hiromichi Ebi; Yasushi Sigeoka; Toshiaki Saeki; Kenji Kawada; Tadahiko Igarashi; Noriko Usubuchi; Ryuzo Ueda; Yasutsuna Sasaki; Hironobu Minami
Journal:  Cancer Chemother Pharmacol       Date:  2005-04-21       Impact factor: 3.333

2.  Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.

Authors:  T Ishikawa; M Utoh; N Sawada; M Nishida; Y Fukase; F Sekiguchi; H Ishitsuka
Journal:  Biochem Pharmacol       Date:  1998-04-01       Impact factor: 5.858

3.  Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer.

Authors:  Chang Sik Yu; Tae Won Kim; Jong Hoon Kim; Won Sik Choi; Hee Cheol Kim; Heung Moon Chang; Min Hee Ryu; Se Jin Jang; Seung Do Ahn; Sang-Wook Lee; Seong Soo Shin; Eun Kyung Choi; Jin Cheon Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-29       Impact factor: 7.038

4.  X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.

Authors:  N Sawada; T Ishikawa; F Sekiguchi; Y Tanaka; H Ishitsuka
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

5.  Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.

Authors:  M A Villalona-Calero; G R Weiss; H A Burris; M Kraynak; G Rodrigues; R L Drengler; S G Eckhardt; B Reigner; J Moczygemba; H U Burger; T Griffin; D D Von Hoff; E K Rowinsky
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

6.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

Authors:  J Schüller; J Cassidy; E Dumont; B Roos; S Durston; L Banken; M Utoh; K Mori; E Weidekamm; B Reigner
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

Review 7.  Clinical pharmacokinetics of capecitabine.

Authors:  B Reigner; K Blesch; E Weidekamm
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Authors:  M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka
Journal:  Eur J Cancer       Date:  1998-07       Impact factor: 9.162

9.  Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.

Authors:  M J O'Connell; J A Martenson; H S Wieand; J E Krook; J S Macdonald; D G Haller; R J Mayer; L L Gunderson; T A Rich
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

10.  Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.

Authors:  Manpreet Bedi; Prajnan Das; John M Skibber; Miguel A Rodriguez-Bigas; George J Chang; Cathy Eng; Robert A Wolff; Nora A Janjan; Sunil Krishnan; Christopher H Crane
Journal:  Gastrointest Cancer Res       Date:  2007-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.